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disease-free survival (DFS) and overall survival (OS) in hormone receptor (HR)-positive breast
cancer patients. The aim of this study was to identify the HR-positive breast cancer women
who need adjuvant tamoxifen for > 5 years.
Methods: Between 1990 and 2004, 1104 HR-positive breast cancer patients who had received
tamoxifen treatment at our institution and had been disease free for at least 6 years were
included in this analysis. Univariate and multivariate analyses of prognostic factors for late
recurrence were performed using the binary logistic regression model.
Results: During a median follow-up period of 10.9 years after surgery, 70 patients died and 99
showed recurrence. In multivariate analysis, age < 40 years (p < 0.001) and lymph node metas-
tasis (p < 0.001) were associated with higher rates of recurrence. We stratified patients into
high-risk (age < 40 years or positive lymph node status, 536 patients) and low-risk (age > 40
years and negative lymph node status, 566 patients) groups. The recurrence rates were
14.6% and 3.5% in the high-risk and low-risk groups, respectively. Patients in the high-risk group
had poorer disease-free survival (p < 0.001) and overall survival (pZ 0.010) than those in the
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Breast cancer is a heterogeneous, phenotypically diverse
disease composed of several biologic and molecular sub-
types that have distinct behaviors and responses to various
therapies. Hormonal receptor (HR)-positive [positive for
estrogen receptor (ER) and/or progesterone receptor (PR)
expression] breast cancer is the most common type of
breast cancer. A robust response to various types of endo-
crine therapy is the dominant feature of HR-positive breast
cancer; endocrine therapy is indispensable for the treat-
ment of this subtype of breast cancer.
Adjuvant tamoxifen therapy for 5 years has resulted in
reduced recurrence and mortality in premenopausal and
postmenopausal women with both node-negative and node-
positive, HR-positive breast cancer.1 To achieve the maximal
efficacy of adjuvant endocrine therapy, adjuvant tamoxifen
beyond 5 years has been studied for decades. However, early
studies recruited relatively few patients and the results of
these studies were inconclusive.2e5 Nonetheless, adjuvant 5-
year tamoxifen therapy has been the standard treatment for
early HR-positive breast cancer in past decades.
Recently, both extended therapy with tamoxifen6,7 and
sequencing therapy with letrozole in postmenopausal
women8 after the completion of 5 years of treatment with
tamoxifen have resulted in an improvement in disease-free
survival (DFS) and overall survival (OS). However, a meta-
analysis of five trials reported that extended adjuvant
tamoxifen could not reduce recurrence or all-cause death in
unselected breast patients.9 Extended tamoxifen treatment
could increase the risk of endometrial cancers and throm-
boembolic diseases, which may compromise the decrease in
breast cancer mortality in HR-positive breast cancer pa-
tients;6,7 this raises the question of which patient subgroups
have a higher risk of recurrence after 5-year tamoxifen
treatmentandwouldbenefitmore fromanadditional 5-years
of endocrine therapy. Therefore, the identification of risk
factors that can predict disease recurrence beyond 5 years
after 5-year tamoxifen therapy for HR-positive breast cancer
may provide additional supporting evidence for the optimal
treatment for those premenopausal patients. Hence, we
sought to retrospectively review our database of HR-positive
breast cancer patients who had completed adjuvant
tamoxifen therapy andwhowere free of disease recurrence6
years postsurgery to identify possible risk factors that result
in a higher risk of late recurrence and mortality.
Materials and methods
Patients
Between 1990 and 2004, all breast cancer patients who
underwent breast cancer surgery at Linkou Chang GungMemorial Hospital (CGMH), Taoyuan, Taiwan were regis-
tered in the CGMH breast cancer databank. Data on patient
demographics, tumor characteristics, surgical procedures,
adjuvant chemotherapy, radiotherapy, hormonal therapy,
disease status, and survival outcomes were retrospectively
collected. The present analysis enrolled stage IeIII HR-
positive breast cancer patients undergoing curative surgery
with or without adjuvant chemotherapy followed by adju-
vant tamoxifen therapy. Patients who were free of disease
6 years after their surgery, regardless of the duration of
their tamoxifen therapy, were included for analysis. Before
1998, the HR status was examined by using a cytosol char-
coal absorption assay, whereas immunohistochemical
staining was used to determine HR status thereafter. As
human epidermal growth factor-2 (HER-2) staining was not
available prior to 2000, HER-2 expression data were not
used. This retrospective analysis was approved by the
Institutional Review Board of CGMH.Treatment
All patients underwent primary surgery consisting of either
modified radical mastectomy (MRM) or partial mastectomy
(PM) with axillary lymph node dissection. Adjuvant radio-
therapy was administered to patients who received PM or
who had pathological stage T3 disease, or more than three
axillary lymph node metastases.10 Adjuvant chemotherapy
was administered to high-risk patients, such as high-risk
node-negative or node-positive cancer. Chemotherapy reg-
imens were administered at the physician’s discretion and
patients’ preference; for example, intravenous cyclophos-
phamide, methotrexate, and 5-fluorouracil (CMF), cyclo-
phosphamide, epirubicin, and 5-fluorouracil (CEF) or CEF
regimens followed by taxanes were utilized in node-positive
disease in accordance with the contemporary international
consensus. Adjuvant endocrine therapy consisted of
tamoxifen (20 mg per day) for 2e5 years; prior to1996, 2
years of tamoxifen treatment was the common duration of
treatment. After the completion of surgery, chemotherapy
and radiotherapy, the patients were followed-up at the
outpatient department with a physical examination every 3
months for the first 2 years, every 6 months for the next 3
years, and every 12 months thereafter; breast mammog-
raphy or ultrasonography every 12 months; chest radiog-
raphy every 12 months; and a complete blood count,
biochemical tests, and measurements of the serum levels of
carcinoembryonic antigen (CEA) and cancer antigen 15-3
(CA15-3) every 6 months for the first 3 years and every 12
months thereafter. Other examinations, such as bone scan-
ning and abdominal ultrasonography, were performed at the
physicians’ discretion. Medical information was obtained by
a periodic review of the charts and by telephone interviews.
The cut-off (data-lock) follow-up time-point was July 2012.
Table 1 Patients’ characteristics (n Z 1104).
Patients (%)
Age, years
< 40 173 (15.7)
40e64.9 810 (73.3)
 65 121 (11.0)
T stage (AJCC)
T1 504 (45.7)
T2 556 (50.3)
T3 37 (3.4)
T4 7 (0.6)
N stage (AJCC)
N0 673 (61.0)
N1 274 (24.8)
N2 101 (9.1)
N3 54 (4.9)
Unknown 2 (0.2)
Grade
1 219 (19.8)
2 383 (34.7)
3 143 (13.0)
Unknown 359 (32.5)
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The description of the cohort used median and range values
for categorical variables. We evaluated clinicopathological
features, including age, tumor size, pathologically involved
lymph nodes, tumor grade, and ER, PR, and HER-2 status.
DFS was defined as the duration from surgery to the diag-
nosis of recurrence or a second primary malignancy. Data
on patients who died without evidence of recurrence or
who were lost to follow-up were censored at the date of
death or their last visit, respectively. OS was defined as the
duration from surgery to death due to any cause. Late
recurrence was defined as the recurrence (including
contralateral breast cancer) that occurred at least 6 years
after primary surgery. Prognostic factors included age,
tumor size, pathologically involved lymph nodes, Scarff-
Bloom-Richardson (SBR) grade, ER, and PR status. Survival
was analyzed using the KaplaneMeier method. Univariate
and multivariate analyses of the association between the
prognostic factors and survival were performed using the
Cox proportional hazard model. Univariate and multivariate
analyses of the odds ratio (OR) of predictive factors were
performed using the binary logistic regression model.ER
þ 988 (89.5)
 116 (10.5)
PR
þ 902 (81.7)
 196 (17.8)
Unknown 6 (0.5)
AJCC Z American Joint Committee on Cancer; ER Z estrogen
receptor; PR Z progesterone receptor.Results
Patient characteristics
A total of 2191 HR positive breast cancer patients were
registered in our databank from 1990 to 2005. Among them,
1104 patients who had received tamoxifen and have been
free of disease for at least 6 years were enrolled for anal-
ysis. The median age was 49.1 years with a range of
36.6e82.5 years. There were 504 (45.7%) patients with
stage T1 disease, 556 (50.3%) with stage T2 disease, and 673
(61.0%) who were node negative. ER and PR statuses were
positive in 988 (89.5%) and 902 (81.7%) patients, respec-
tively. A total of 756 women underwent chemotherapy
including a CMF regimen (n Z 492), anthracycline-based
regimen without taxanes (n Z 218) or with taxanes
(n Z 46). In the patients in this cohort, those who had a
longer disease-free interval had favorable clinicopatholog-
ical profiles compared with those patients who had disease
recurrence within 6 years postsurgery (Table 1).
Outcome analysis
Of the 1104 patients, there were 70 deaths and 99 re-
currences during the study period. Nine patients had first
recurrence with contralateral breast cancer. The median
follow-up period was 10.9 years from the date of surgery.
The median time to death and recurrence were both not
reached at the time of this analysis. The 10-year and esti-
mated 20-year DFS rates were 91.5% and 85.6%, respec-
tively, whereas the 10-year and estimated 20-year OS rates
were 95.0% and 87.3%, respectively. During the follow-up
period, there were only two (0.2%) patients who developed
endometrial cancer. One patient had endometrial cancer
followed by late recurrence after completion of tamoxifen
and another occurred after later recurrence. In order todelineate and identify potential prognostic factors among
this group of patients, we performed univariate and
multivariate analyses of late recurrence rate, DFS, and OS.
Clinicopathological factors predictive of late
recurrence rate
Regarding the recurrence rate, patients with age < 40
years, age > 65 years, stage T2e4 disease, positive lymph
nodes, and positive ER status had a significantly higher
recurrence rate than patients aged 40e64.9 years with
stage T1 disease, negative lymph nodes, and negative ER
status. The details of predictive factors for recurrence rate
are provided in Table 2.
In multivariate analysis, age < 40 years (OR Z 4.21,
p < 0.001), and N stage (OR Z 2.667, OR Z 3.768, and
OR Z 6.103, for N1, N2, and N3, respectively vs. N0) were
associated with higher recurrence rates (Table 2). The
recurrence rates of N0, N1, N2, and N3 were 5.1%, 12.8%,
15.8%, and 24.1%, respectively.
Clinicopathological prognostic factors of disease-
free survival
Univariate analysis of DFS revealed that age < 40 years, age
> 65 years, positive lymph nodes, and positive ER status
Table 2 Univariate and multivariate analysis of late recurrence rate.
Univariate analysis Multivariant analysis
No. of events/total
no. (recurrence rate, %)
p OR (95% CI) p
Age, y 0.002
< 40 27/173 (15.6) 2.567 (1.544e4.270) < 0.001
40e64.9 59/810 (7.3)
 65 13/121 (10.7) 1.616 (0.825e3.167) 0.162
T stage(AJCC) 0.031
T1 35/504 (6.9) 1
T2e4 64/600 (10.7) 1.182 (0.751e1.861) 0.469
N stage(AJCC) < 0.001 < 0.001
N0 34/673 (5.1) 1
N1 35/274 (12.8) 2.667 (1.604e4.436) < 0.001
N2 16/101 (15.8%) 3.768 (1.951e7.275) < 0.001
N3 13/54 (24.1) 6.103 (2.923e12.744) < 0.001
Grade 0.129
1 14/219 (6.4)
2 37/383 (9.6)
3 18/143 (12.6)
ER 0.028
þ 95/988 (9.6) 2.718 (0.968e7.634) 0.058
 4/116 (3.4) 1
PR 0.607
þ 79/902 (8.7)
 20/202 (9.9)
AJCCZ American Joint Committee on Cancer; CIZ confidence interval; ERZ estrogen receptor; ORZ odds ratio; PRZ progesterone
receptor.
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stage > 1 had a trend toward poorer DFS compared with
those with T stageZ 1 (HR 1.501, pZ 0.054), but the trend
was not significant. By multivariate analysis, only age < 40
years (HR 2.342, p < 0.001), age > 65 years (HR 1.943,
pZ 0.038), and positive lymph nodes (HR 2.425, 3.275, and
5.299 for N1, N2, and N3, respectively vs. N0, p < 0.001)
were independent prognostic factors for DFS (Table 3).Table 3 Univariate and multivariate analysis of disease-free su
Univariate analy
HR (95% CI)
Age, y
< 40 2.281 (1.446e3.597)
40e64.9 1
 65 1.834 (1.005e3.347)
T stage (AJCC) ( T2 vs. T1) 1.501 (0.993e2.267)
N stage (AJCC)
N0 1
N1 2.446 (1.526e3.922)
N2 3.117 (1.720e5.648)
N3 5.287 (2.787e10.028)
Grade (2/3 vs. 1) 1.521 (0.846e2.737)
ER (þ vs. ) 2.827 (1.039e7.691)
PR (þ vs. ) 0.766 (0.496e1.183)
AJCC Z American Joint Committee on Cancer; CI Z confiden
PR Z progesterone receptor.Clinicopathological prognostic factors of overall
survival
Univariate analysis of OS revealed that age > 65 years, T
stage > 1, and positive lymph nodes were associated with
an unfavorable OS. Age > 65 years (HR 5.874, p < 0.001)
and positive lymph nodes (HR 1.898, 3.216, and 4.019 forrvival.
sis Multivariant analysis
p HR (95% CI) p
0.001 0.001
< 0.001 2.342 (1.479e3.707) < 0.001
0.048 1.943 (1.037e3.641) 0.038
0.054 1.114 (0.728e1.704) 0.618
< 0.001 < 0.001
< 0.001 2.425 (1.502e3.915) < 0.001
< 0.001 3.275 (1.787e6.003) < 0.001
< 0.001 5.299 (2.745e10.229) < 0.001
0.161
0.042 2.514 (0.922e6.854) 0.072
0.230
ce interval; ER Z estrogen receptor; HR Z hazard ratio;
Figure 1 The late recurrence rates in subgroups classified by
risk factors. Patients were classified into high-risk and low-risk
groups according to the involvement of their lymph nodes (LN),
followed by age. The overall late recurrence rates were 14.6%
and 3.5% in the high-risk and low-risk groups, respectively.
Extended tamoxifen for HRþ breast cancer women 253N1, N2, and N3, respectively vs. N0, p < 0.001) were in-
dependent prognostic factors of OS, as determined by
multivariate analysis. Patients with T stage > 1 had a trend
toward poorer OS (HR 1.731, p Z 0.053) by multivariate
analysis (Table 4).
Identification of high risk patients
Fig. 1 illustrates the patients’ allocations based on the
identified factors that were predictive of the late recur-
rence rate. We stratified these patients into high-risk and
low-risk groups. Patients aged < 40 years and/or with
positive lymph nodes were placed in the high-risk group
(536 patients), whereas the remainder (including those
aged > 40 years and with negative lymph nodes) were
placed in the low-risk group (566 patients). The recurrence
rates were 14.6% and 3.5% in high-risk and low risk groups,
respectively.
The annual hazard of recurrence between the high-risk
and low risk groups is shown in Fig. 2. The annual hazard of
recurrence was around 1% after 6 years postsurgery in the
low risk group. By contrast, the annual hazard of recur-
rence accounted for 3e5% between postoperative Year 6
and Year 10, and then decreased gradually.
From using KaplaneMeier estimation, the estimated 10-
year (from Year 6) and 15-year recurrence rates were 3.1%
and 7.7%, respectively in the low-risk group and 14.7% and
22%, respectively, in the high-risk group. Estimated 10-year
and 15-year mortality rates were and 3.5% and 7.4%,
respectively, in the low-risk group and 7.4% and 16.7%,
respectively, in the high-risk group. The high-risk patients
had poorer DFS (p < 0.001) and OS (pZ 0.010) than low-risk
patients (Fig. 3).
Discussion
HR-positive breast cancer patients have a modest increase
in annual recurrence odds 2e3 years after completing
adjuvant tamoxifen. Saphner et al11 have demonstratedTable 4 Univariate and multivariate analysis of overall survival
Univariate analy
HR (95% CI)
Age, y
< 40 0.976 (0.434e2.193)
40e64.9 1
 65 5.692 (3.455e9.378)
T stage (AJCC) ( T2 vs. T1) 2.306 (1.348e3.944)
N stage (AJCC)
N0 1
N1 1.759 (0.973e3.178)
N2 3.628 (1.921e6.851)
N3 3.553 (1.608e7.851)
Grade (2/3 vs. 1) 1.115 (0.566e2.198)
ER (þ vs. ) 1.401 (0.563e3.484)
PR (þ vs. ) 0.766 (0.448e1.312)
AJCC Z American Joint Committee on Cancer; CI Z confiden
PR Z progesterone receptor.that the annual hazard of recurrence remains at 4e5% up to
12 years after primary therapy in HR-positive patients. The
existence of late recurrence beyond 10 years in a small
proportion of patient remains an unsolved, disturbing issue.
The present study followed patients up to 20 years in a
single institution; the estimated 20-year DFS was 85.6% in
1104 patients who had ever received adjuvant tamoxifen
and who were free of disease at 6 years postmastectomy.
We also found that patients with positive nodes or those
who were < 40 years of age at diagnosis had a statistically
significant increased risk of late recurrence and death. The
annual odds of recurrence for patients with high-risk fac-
tors are sustained, even beyond 15 years. In this cohort,
patients with positive lymph nodes and/or a young age
(< 40 years) had an increased later recurrence rate of
14.6% following the completion of adjuvant tamoxifen
therapy. By contrast, the patients with negative lymph.
sis Multivariant analysis
p HR (95% CI) p
0.001 0.001
< 0.001 0.991 (0.439e2.238) 0.982
0.048 5.874 (3.502e9.852) < 0.001
0.054 1.731 (0.993e3.017) 0.053
< 0.001 < 0.001
1
< 0.001 1.898 (1.036e3.475) 0.038
< 0.001 3.216 (1.617e6.167) < 0.001
< 0.001 4.019 (1.783e9.060) < 0.001
0.752
0.468
0.332
ce interval; ER Z estrogen receptor; HR Z hazard ratio;
Figure 2 Annual recurrence hazard rates in high-risk and low-risk groups. The annual hazard of recurrence wasw 1% at 6 years
postsurgery in the low-risk group. By contrast, the annual hazard of recurrence accounted for 3e5% between postoperative Year 6
and Year 10 and then decreased gradually.
Figure 3 Analyses of disease-free survival and overall survival in high-risk and low-risk groups, KaplaneMeier estimates of the
probability of disease-free survival in the low-risk (patients  40 years of age without metastatic lymph nodes) and high-risk groups
(patients < 40 years of age and/or with metastatic lymph nodes); (B) KaplaneMeier estimates of the probability of overall survival
in the low-risk and high-risk groups.
254 C.-E. Wu et al.nodes and who are > 40 years of age have a very low
recurrence rate of 3.5%. This study implies that identifying
factors that can predict the late recurrence of adjuvant
tamoxifen of HR-positive breast cancer may help clinicians
to justify when patients have completed 5 years of adju-
vant tamoxifen therapy.
In the current study, we found that lymph node status
was an important predictive factor of late recurrence. This
feature has been repeatedly confirmed or validated by
many studies,11 including a few extended clinical trials. For
example, Tormey et al4 found that adjuvant tamoxifen
therapy beyond 5 years resulted in a trend toward improved
DFS in patients with lymph node-positive, ER-positive
breast cancer (p Z 0.01), but Fisher et al2 failed to
demonstrate an additional improvement in DFS and OS in
lymph node-negative, ER-positive breast cancer. Similarly,
in the MA 17 study, a benefit for OS was only observed in thenode-positive subgroup.12 Although subgroup analysis of the
ALTAS trial showed that 10-years of adjuvant tamoxifen
therapy had a similar benefit in both lymph node-positive
and lymph node-negative breast cancer patients, the ab-
solute reduction of recurrence was only 2% in the latter
group.6 Recently, a meta-analysis of extended adjuvant
tamoxifen for early breast cancer demonstrated that pa-
tients with positive lymph node involvement rather than
unselected patients could benefit from extended adjuvant
tamoxifen.9
We also found that patients < 40 years of age had a
significantly shortened DFS (HR 2.342) and higher recur-
rence rate (OR 2.567) than patients 40e64.9 years of age.
In node negative breast cancer patients, being < 35 years
of age at diagnosis is an established poor prognostic fac-
tor.13,14 In the Asian population, young age is also associ-
ated with poor prognostic factors; a study of Korean
Extended tamoxifen for HRþ breast cancer women 255nationwide data showed that patients of a very young age
(< 35 years) with HR-positive breast cancer had a worse
prognosis than older patients (35e50 years), regardless of
their tumor size or lymph node status, even in those
receiving hormonal therapy.15 A similar report showed that
an age of 40 years or younger is a poor prognostic factor in
Taiwanese women.16 Despite meta-analyses suggesting that
tamoxifen can improve the odds of recurrence and death
regardless of age, patients younger than 35 years or 40
years are still more likely to have poor outcomes. The fact
that chemotherapy-induced amenorrhea was associated
with favorable outcomes in a line of retrospective data17,18
indicates that inadequate endocrine suppression with
young patients is one of the main reasons for the poor
outcomes in this patient group. Retrospective and subset
analyses further support the notion that ovarian suppres-
sion maybe benefit young female breast cancer patients.19
Among younger patients (< 50 years), the Early Breast
Cancer Trialists’ Collaborative Group meta-analysis from
1998 reported that adjuvant tamoxifen therapy lacked a
definite benefit in trials of < 2 years, but it provided a
benefit for recurrence and survival in older patients.20
Adjuvant ovarian ablation was also demonstrated to pro-
vide a substantial benefit to long-term survival in younger
patients.21 Taken together, these results suggest that a
longer duration of adjuvant hormonal therapy for young
women with HR-positive breast cancer maybe an option to
improve survival.
The current standard for adjuvant endocrine therapy for
HR positive premenopausal patients is 5-year tamoxifen
therapy; however, with a high rate of late recurrence, it
remains a suboptimal standard of therapy. The National
Surgical Adjuvant Breast and Bowel Project (NSABP) B-14
study showed that extended tamoxifen therapy for up to 10
years did not prolong survival, but it increased the risk of
endometrial hyperplasia/cancer and thromboembolism.2,22
This issue has been partially improved because the National
Cancer Institute of Canada Clinical Trials Group MA.17 study
showed that extended adjuvant letrozole is superior to
placebo in terms of DFS, but it provides only a marginal
benefit for node-positive postmenopausal patients in OS.
For premenopausal breast cancer patients, the optimal
strategy for improving outcome remains unsolved. Thus,
more aggressive therapy should be considered and
extended tamoxifen is one of the options. Recently, both
the Adjuvant Tamoxifen: Longer Against Shorter (ATLAS)
and adjuvant TamoxifendTo offer more? (aTTom) Phase III
studies demonstrated that extended therapy with tamox-
ifen for 10 years can decrease recurrence and mortality
more than conventional tamoxifen therapy for 5 years.6,7 In
the ATLAS trial, extended tamoxifen therapy reduced the
cumulative risk of recurrence (21.4% vs. 25.1%) and breast
cancer mortality (12.2% vs. 15.0%) during Years 5e14.6 In
the aTTom study, continuing tamoxifen therapy reduced
breast cancer recurrence (580/3468 vs. 672/3485,
pZ 0.003) and breast cancer mortality (392 vs. 443 deaths
after recurrence, pZ 0.05).7 However, because ER-positive
breast cancer is a disease with a favorable prognosis, the
majority of patients actually did not have disease recur-
rence after 5-year tamoxifen therapy. Considering the un-
toward effects from long-term tamoxifen therapy, the
benefits of a protracted course of adjuvant tamoxifen inpremenopausal patients should be carefully weighed
against the risks. We found that the actual recurrence rates
were 3.5% in low-risk patients (age  40 years and node-
negative) and 14.6% in the remaining high-risk patients. In
a patient that has an estimated recurrence rate of 3.5% at
10 years, a treatment that would provide a modest benefit
for survival at the expense of an almost identical risk of
life-threatening side effects remains controversial.23
HR positive disease was thought to be a genetically
heterogeneous disease with a varied clinical course and
treatment response. In the near future, we will not be
satisfied using only clinicopathological features to build a
treatment strategy for individual patients. For example, a
recently described biomarker, the HOXB13/IL17BR expres-
sion index, can predict not only later recurrence and sur-
vival,24 but also the efficacy of extended adjuvant letrozole
in postmenopausal patients receiving adjuvant tamox-
ifen.25 The HOXB13/IL17BR expression index correlated
significantly with predictors of poor prognosis, such as HER-
2 amplification, S-phase fraction, and the number of posi-
tive lymph nodes. However, it was only associated with
prognosis in node-negative breast cancer and not in node-
positive breast cancer.26 In addition, the evidence of
HOXB13/IL17BR in premenopausal or young women with
breast cancer is limited. The breast cancer index, a gene
expression-based biomarker combining HOXB13/IL17BR and
five-gene molecular grade indices, could be a good prog-
nostic factor for early and late recurrence in HR-positive,
node-negative breast cancer.27,28 Genomic data generated
from microarray analysis or other molecular studies have
been incorporated into clinical trials such as the micro-
arRAy-prognoSTics-in-breast-cancER (RASTER) study.29
Therefore, further studies are warranted to identify
possible biomarkers to predict recurrence in HR-positive
breast cancer.
There were several limitations in the current study: (1)
this was a single-institution retrospective study with the
inherited bias typical of this type of research design; (2) we
did not analyze factors such as HER-2 status, Ki67 expres-
sion, and pathologic features such as lymphovascular in-
vasion (LVI). However, we analyzed the role of grading
instead of Ki67, and the role of LVI has been shown to be
limited in node-negative breast cancer. Also this study was
limited by the fact that we did not routinely perform HER-2
analysis before 2000. The late presentation of breast can-
cer after the HER-2 era and posttrastuzumab treatment in
such patient groups will be an interesting issue for study in
the upcoming decade; and (3) the compliance, precise
duration of tamoxifen therapy, and side effects of tamox-
ifen were not evaluated in a retrospective nature. Howev-
er, the target population have all been treated and
followed at our institution and have been confirmed to be
free of disease for 6 years. Therefore, our focus was to
identify the risk factors for developing late recurrence in
this group of patients. The results generated from this
databank require validation in the future.
In conclusion, based on this study, for premenopausal
women, we recommend that HR-positive breast cancer
patients younger than 40 years of age or with positive
lymph nodes should consider extended tamoxifen adjuvant
therapy beyond 5 years to reduce the risk of late recur-
rence and to prolong survival. Those patients that become
256 C.-E. Wu et al.postmenopausal during adjuvant tamoxifen therapy should
shift to aromatase inhibitors. Others should be carefully
justified for a relatively narrow therapeutic window. For
postmenopausal, node-positive women, treatment with
aromatase inhibitors for 5 years remains the first priority.
The search for optimal adjuvant hormonal therapy for HR-
positive breast cancers, including genomic approaches, is a
never-ending journey.References
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